Article History
Received: 27 January 2022
Revised: 11 May 2022
Accepted: 20 May 2022
First Online: 11 June 2022
Competing interests
: J.L.B.: consultant: Bluebird Bio, Calico, Neurogene, Passage Bio; Board of Directors: wFluidx; Stock: Orchard Therapeutics; royalties: Manson Publishing, BioMerieux (spouse); research support: NIH; Leukodystrophy Foundation; European Leukodystrophy Association. T.P.: no conflicts of interest. Research support: NIH, Ehlers Danlos Society, Canadian Institutes of Health Research. P.W.: no conflicts of interest. Research support: NIH, Aditional Ventures Foundation.
Free to read: This content has been made available to all.